Company: ANIX
Filing Date: 2025-09-10
Form Type: 10-Q
Source: 0001493152-25-013000
Chunk: 24

Company: Anixa Biosciences Inc
Filing Date: 2025-09-10
Form: 10-Q
Item: Part I, Item 1
Chunk 24
---
 -  
     14,522 
  
    Total
    financial assets 
    $1,448  
    $14,534  
    $-  
    $15,982 

    13

The
following table presents the hierarchy for our financial assets measured at fair value on a recurring basis as of October 31, 2024 (in
thousands):

    Level
    1  
    Level
    2  
    Level
    3  
    Total 
  
    Money
    market funds: 

    Cash
    equivalents 
    $1,170  
    $-  
    $-  
    $1,170 
  
    U.S.
    treasury bills: 

    Short-term
    investments 
     -  
     18,653  
     -  
     18,653 
  
    Total
    financial assets 
    $1,170  
    $18,653  
    $-  
    $19,823 

Our
non-financial assets that are measured at fair value on a non-recurring basis are property and equipment and other assets which are measured
using fair value techniques whenever events or changes in circumstances indicate a condition of impairment exists. The estimated fair
value of prepaid expenses and other current assets, accounts payable and accrued expenses approximates their individual carrying amounts
due to the short-term nature of these measurements. Cash equivalents are stated at carrying value which approximates fair value.

5.
ACCRUED EXPENSES

Accrued
expenses consist of the following as of:

 SCHEDULE OF ACCRUED EXPENSES

    July
    31,  
    October
    31, 

    2025  
    2024 

    (in
    thousands) 
  
    Payroll
    and related expenses 
    $865  
    $1,126 
  
    Accrued
    royalty and contingent legal fees 
     626  
     626 
  
    Accrued
    other 
     260  
     194 
  
    Accrued
    expenses 
    $1,751  
    $1,946 

6.
NET LOSS PER SHARE OF COMMON STOCK

Basic
net loss per common share (“Basic EPS”) is computed by dividing net loss by the weighted average number of common shares
outstanding. Diluted